What is the current role of ctDNA in guiding the selection of adjuvant treatment for stage II-IIIA melanoma?

There are only retrospective, not prospective data on Natera’s tumor-informed ctDNA platform (Signatera). I would be cautious in using the ctDNA result for clinical decision-making. The gold standard is still the radiographic imaging - there is no test that will replace being able to see a measurabl...

Unless a biomarker is shown to improve survival, and an efficacious treatment is available, any of this testing should be done under a research study that tests an ethical hypothesis, preferably in a randomized study. First, do not harm, second many lead time biases.

While I agree with prior opinions, I find the ctDNA results to be informative and, at a minimum, valuable for guiding surveillance strategies and vigilance in patients who are ctDNA-detectable or show rising ctDNA levels.

I fully support adhering to NCCN guidelines with respect to adjuvant treatment...